DRF Luftrettung

DRF Aviation Services launches on October 1, 20261.10.2026 11:29:07 CEST | DRF Luftrettung | Press release

Filderstadt, Germany - DRF Luftrettung and DRF Maintenance are joining forces: the newly established DRF Aviation Services combines the two companies’ technical expertise built on more than 50 years of experience in helicopter maintenance, modifications and services. As a “one-stop shop”, DRF Aviation Services provides the full range of services from a single source. Helicopter operators benefit from high levels of reliability and innovative capability.
Green Power Denmark

Ny lov er tiltrængt krisehjælp – nu skal Energinet bygge mere og hurtigere1.10.2026 10:41:51 CEST | Green Power Denmark | Pressemeddelelse

Folketinget har torsdag vedtaget den lov, der på den korte bane skal hjælpe med at prioritere i køen af kunder, der ønsker tilslutning til elnettet. Allerede nu skal arbejdet med at fjerne barrierer fortsætte, så Energinet kan nedbringe ventetiden på at udrulle mere transmissionsnet. Det er helt afgørende med fortsat politisk fremdrift for at få Danmark ud af kapacitetskrisen, mener Green Power Denmark.
LEO Pharma

LEO Pharma presents new tralokinumab data at EADV 2026 highlighting real-world outcomes and quality of life in adults and adolescents with atopic dermatitis (AD) involving high-burden areas1.10.2026 10:30:00 CEST | LEO Pharma | Pressemeddelelse

New findings from a subgroup analysis of the 12-month TRACE study show that more than 70% of adults whose Atopic Dermatitis (AD) affected multiple high-burden areas – such as the head and neck, hands and feet, or genitals – had reduced involvement of those areas after 12 months of treatment with tralokinumab.1 New pre-specified and post hoc analyses from the phase 3 ADHAND trial show significantly greater improvements in quality of life, daily function and sleep at Week 16 with tralokinumab monotherapy than with placebo in adults with AD and moderate-to-severe hand involvement, with the two treatment groups separating within two weeks.2,3 In a post hoc analysis, adolescents aged 12-17 years treated across the phase 3 ECZTRA 6 trial and its ECZTEND extension, response rates remained high and stable through most of the extension period, and no new safety concerns were identified.5
  • 1
  • 2
  • 3
  • 4
  • 5
  • Sidste
  • >>
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye